Browse TNFSF14

Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Tumor necrosis factor ligand superfamily member 14, membrane form: Cell membrane; Single-pass type II membrane protein.; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 14, soluble form: Secreted.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm.
Domain PF00229 TNF(Tumour Necrosis Factor) family
Function

Cytokine that binds to TNFRSF3/LTBR. Binding to the decoy receptor TNFRSF6B modulates its effects. Activates NFKB, stimulates the proliferation of T-cells, and inhibits growth of the adenocarcinoma HT-29. Acts as a receptor for Herpes simplex virus.

> Gene Ontology
 
Biological Process GO:0000768 syncytium formation by plasma membrane fusion
GO:0001776 leukocyte homeostasis
GO:0002260 lymphocyte homeostasis
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006949 syncytium formation
GO:0007159 leukocyte cell-cell adhesion
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007253 cytoplasmic sequestering of NF-kappaB
GO:0007520 myoblast fusion
GO:0008588 release of cytoplasmic sequestered NF-kappaB
GO:0009612 response to mechanical stimulus
GO:0010466 negative regulation of peptidase activity
GO:0010818 T cell chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:0010820 positive regulation of T cell chemotaxis
GO:0010830 regulation of myotube differentiation
GO:0010831 positive regulation of myotube differentiation
GO:0010951 negative regulation of endopeptidase activity
GO:0014902 myotube differentiation
GO:0017038 protein import
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031503 protein complex localization
GO:0032103 positive regulation of response to external stimulus
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032507 maintenance of protein location in cell
GO:0032943 mononuclear cell proliferation
GO:0033157 regulation of intracellular protein transport
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034504 protein localization to nucleus
GO:0034612 response to tumor necrosis factor
GO:0040017 positive regulation of locomotion
GO:0042098 T cell proliferation
GO:0042110 T cell activation
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042308 negative regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042346 positive regulation of NF-kappaB import into nucleus
GO:0042347 negative regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042692 muscle cell differentiation
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042992 negative regulation of transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0042994 cytoplasmic sequestering of transcription factor
GO:0043029 T cell homeostasis
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0044744 protein targeting to nucleus
GO:0045185 maintenance of protein location
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045663 positive regulation of myoblast differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045861 negative regulation of proteolysis
GO:0046651 lymphocyte proliferation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046823 negative regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048247 lymphocyte chemotaxis
GO:0048872 homeostasis of number of cells
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051051 negative regulation of transport
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051155 positive regulation of striated muscle cell differentiation
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051220 cytoplasmic sequestering of protein
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051235 maintenance of location
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051651 maintenance of location in cell
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060142 regulation of syncytium formation by plasma membrane fusion
GO:0060143 positive regulation of syncytium formation by plasma membrane fusion
GO:0060326 cell chemotaxis
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071356 cellular response to tumor necrosis factor
GO:0071496 cellular response to external stimulus
GO:0071593 lymphocyte aggregation
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0090316 positive regulation of intracellular protein transport
GO:0090317 negative regulation of intracellular protein transport
GO:1900180 regulation of protein localization to nucleus
GO:1900181 negative regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901623 regulation of lymphocyte chemotaxis
GO:1901739 regulation of myoblast fusion
GO:1901741 positive regulation of myoblast fusion
GO:1902532 negative regulation of intracellular signal transduction
GO:1902593 single-organism nuclear import
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903533 regulation of protein targeting
GO:1903828 negative regulation of cellular protein localization
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904590 negative regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004869 cysteine-type endopeptidase inhibitor activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0030414 peptidase inhibitor activity
GO:0032813 tumor necrosis factor receptor superfamily binding
GO:0043027 cysteine-type endopeptidase inhibitor activity involved in apoptotic process
GO:0043028 cysteine-type endopeptidase regulator activity involved in apoptotic process
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04064 NF-kappa B signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFSF14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFSF14 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26977880Colon AdenocarcinomaResistant to immunotherapyOur data indicate that targeting LIGHT might be a potent strategy to increase the responses to checkpoint blockades and other immunotherapies in non-T cell-inflamed tumors.
22511579Breast CarcinomaPromote immunityLIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response.
19701890LeukemiaPromote immunityThe TNF member LIGHT also known as TL4 or TNFSF14) can play a major role in cancer control via its two receptors; it induces tumor cell death through lymphotoxin-beta receptor (LT-betaR) and ligation to the herpes virus entry mediator (HVEM) amplifies the immune response. By studying the effect of LIGHT in the transcriptional profile of a lymphoid malignancy, we found that HVEM, but not LT-betaR, stimulation induces a significant increase in the expression of chemokine genes such as IL-8, and an unexpected upregulation of apoptotic genes. This had functional consequences, since LIGHT, or HVEM mAb, thus far known to costimulate T- and B-cell activation, induced chronic lymphocytic leukemia cell death. Many of the mediators involved were identified here, with an apoptotic pathway as demonstrated by caspases activation, decrease in mitochondrial membrane potential, upregulation of the pro-apoptotic protein Bax, but also a role of TRAIL. HVEM Moreover, HVEM induced endogenous TNF-alpha production and TNF-alpha enhanced HVEM-mediated cell death.
29603739glioblastomaPromote immunityThus, peptide-mediated LIGHT targeting is a highly translatable approach in primary brain cancer to reduce vascular leakiness and enhance immunotherapy.
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFSF14 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFSF14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1590.555
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1050.825
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3510.378
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4320.399
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8030.528
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0270.984
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4590.459
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0130.263
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.190.845
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3430.66
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1970.858
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3860.0932
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFSF14 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF14.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFSF14 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFSF14 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFSF14
Nametumor necrosis factor (ligand) superfamily, member 14
Aliases LIGHT; LTg; HVEM-L; CD258; HVEML; delta transmembrane LIGHT; herpes virus entry mediator ligand; herpesvirus ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFSF14 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.